Dr. Raj Yadav is a PKPD Scientist in Development Sciences of Research & Early Development organization at Genentech, South San Francisco, California, USA. His work focuses on leading the PKPD efforts to guide the design, delivery, and development of biologics molecules (bispecifics, fusion proteins and other novel antibody-based therapeutic modalities) in early-stage research to post-marketing. Prior to joining Genentech, he completed his Ph.D. in translational antimicrobial PKPD, modeling and simulations from Monash Institute of Pharmaceutical Sciences, Monash University, Australia. His previous work in Bristol Myers Squibb Biocon R & D Center, India, focuses on preclinical DMPK research to translational PK/PD modeling & Simulation, and first-in-human dose and dosage regimen selection for small molecules and monoclonal antibodies. Dr. Yadav is an author of 20 publications in high impact prestigious journals covering antibodies, antibiotics, translational PKPD modeling and simulations and optimization of clinical dosage regimens for critically-ill patients. He also serves as a reviewer of several reputed journals in the field and currently a member of the scientific advisory board to the Journal of Pharmaceutical Sciences.